Jacob Hickman

Mr. Jacob Hickman


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2026 in Proteomes
Verified
Journal Article
Open access
PDF file
ZWZhennan Wu
Zhennan Wu
SGSachin Anil Ghag
Sachin Anil Ghag
MSMd Hasan Imam Shihab
Md Hasan Imam Shihab
AVAatman Pushkarkumar Vasoya
Aatman Pushkarkumar Vasoya
VSVinamrata Sharma
Vinamrata Sharma
MHMenghao Huang
Menghao Huang
Obesity, type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), and dual-etiology metabolic dysfunction-associated alcohol-related liver disease (MetALD) form an overlapping metabolic dysfunction spectrum, rather than a single linear disease sequence. Proteomics offers a functional readout of this spectrum by measuring proteins, proteoforms, and protein species involved in tissue injury, inflammation, metabolic stress, and inter-organ communication. This review asks how proteomic data can support mechanism-based stratification, rather than simply generate disease-associated signatures. We summarize advances in circulating and tissue-based proteomics across obesity, T2D, MASLD/MASH, and MetALD, highlighting shared and disease-specific pathways such as mitochondrial dysfunction, extracellular matrix remodeling, immune activation, proteostasis stress, and endocrine crosstalk. We emphasize that proteomic clusters should be considered candidate endotypes only when they are reproducible, mechanistically coherent, linked to tissue or causal evidence, and clinically informative. We also evaluate bioinformatics and biostatistical strategies needed for reliable interpretation, including preprocessing, missing-data handling, normalization, longitudinal modeling, multi-omics integration, protein quantitative trait locus (pQTL) analysis, colocalization, and Mendelian randomization. Finally, we discuss how proteoforms, post-translational modifications (PTMs), and platform-dependent proteome complexity shape interpretation. Together, these concepts provide practical guidance for moving from proteomic signatures to candidate endotypes and for prioritizing clinically useful biomarkers and therapeutic targets.